Indeed, a previous study showed that enhanced expression of CX3CL1 in the tumor improves control of the established tumor in multiple preclinical models, including B16 melanoma, by NK-cell– and T-cell–dependent mechanisms (30, 48, 49). This evidence concerns the gene CX3CL1 and melanoma.